Cytokines News and Research

Latest Cytokines News and Research

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.

16 Jul 2014

New tools for detecting and monitoring TB in captive elephants

Mycobacterium tuberculosis, the organism that causes tuberculosis in humans, also afflicts Asian (and occasionally other) elephants. Diagnosing and treating elephants with TB is a challenge, however, as little is known about how their immune systems respond to the infection.

16 Jul 2014

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.

10 Jul 2014

Researchers find unique cell type that can protect against uveitis

Researchers at the National Eye Institute (NEI) have found a unique cell type that, in tests on mice, can protect against uveitis—a group of inflammatory diseases that affect the eye and can cause vision loss.

1 Jul 2014

Small antioxidant molecules suppress colon cancer associated with colitis

Researchers from Case Western Reserve and Dartmouth universities have shown that a class of small antioxidant molecules carries enormous promise for supressing colon cancer associated with colitis.

25 Jun 2014

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today it has in-licensed BL-1110, a novel compound for the treatment of neuropathic pain.

23 Jun 2014

New driver of atherosclerosis may prove to be promising therapeutic target

A new driver of atherosclerosis has been identified by researchers at UT Southwestern Medical Center. This molecule, known as 27HC (27-hydroxycholesterol), has been found to exacerbate the development of the condition, and may prove to be a promising therapeutic target.

20 Jun 2014

Type I interferons can block development of allergy- and asthma-driving Th2 cells

A mechanism that could underlie the development of cells that drive asthma and allergies has been uncovered by immunology researchers at UT-Southwestern Medical Center.

17 Jun 2014

Mechanisms of recurrent bacteria AOM in children under scrutiny

The immune response in young children with bacterial acute otitis media differs between individuals who are prone to such infection and those who are not, US researchers have shown.

16 Jun 2014

Using placental cells to repair damaged tissues: an interview with Zami Aberman, CEO, Pluristem Therapeutics

We start with birth and we collect the cells after C-section. The reason for that is we have to have the mother sign a consent letter that she is donating the placenta and, on top of that, we have to have a blood sample from the mother to test for any viral contamination.

16 Jun 2014

Exercise transiently suppresses inflammation in rheumatic disease

Research findings presented today at the European League Against Rheumatism Annual Congress suggest that exercise transiently suppresses local and systemic inflammation, reinforcing the beneficial effects of exercise and the need for this to be regular in order to achieve clinical efficacy in rheumatic disease.

12 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer.

10 Jun 2014

PGFX Patent Holdings acquires proprietary methods, devices, intellectual property from Orogen Biosciences

On Friday, April 18th PGFX Patent Holdings, operating as Heritage Biosciences, LLC made an asset acquisition of proprietary methods, devices and intellectual property from Orogen Biosciences, Inc.

31 May 2014

Researchers develop active agents that may improve healing of inflammatory illnesses

It is something like the police force of our body: the immune system. It disables intruding pathogens, it dismantles injured tissue and boosts wound healing. In this form of 'self-defense' inflammatory reactions play a decisive role.

27 May 2014

New compound restores learning, memory and other symptoms of AD in mice

A molecular compound developed by Saint Louis University scientists restored learning, memory and appropriate behavior in a mouse model of Alzheimer's disease, according to findings in the May issue of the Journal of Alzheimer's Disease.

21 May 2014

Innate immune response may warn of chronic multisite musculoskeletal pain

An enhanced innate immune response may be an indicator of the onset or prolongation of chronic, multisite musculoskeletal pain, cross-sectional study findings suggest.

19 May 2014

Link found between antibiotic use in babies and asthma

New research has shed light on how treating babies with antibiotics may lead to an increased risk for asthma.

15 May 2014

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results and operational highlights for the quarter ended March 31, 2014.

15 May 2014

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

AstraZeneca today announced that MedImmune, its global biologics research and development arm, will present Phase IIb data on two novel investigational molecules – benralizumab and tralokinumab – at the upcoming American Thoracic Society 2014 International Conference being held in San Diego, California, 16-21 May.

14 May 2014

Cytokines News and Research

Latest Cytokines News and Research

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

New tools for detecting and monitoring TB in captive elephants

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Researchers find unique cell type that can protect against uveitis

Small antioxidant molecules suppress colon cancer associated with colitis

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

New driver of atherosclerosis may prove to be promising therapeutic target

Type I interferons can block development of allergy- and asthma-driving Th2 cells

Mechanisms of recurrent bacteria AOM in children under scrutiny

Using placental cells to repair damaged tissues: an interview with Zami Aberman, CEO, Pluristem Therapeutics

Exercise transiently suppresses inflammation in rheumatic disease

Celsion signs definitive asset purchase agreement to acquire EGEN

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

PGFX Patent Holdings acquires proprietary methods, devices, intellectual property from Orogen Biosciences

Researchers develop active agents that may improve healing of inflammatory illnesses

New compound restores learning, memory and other symptoms of AD in mice

Innate immune response may warn of chronic multisite musculoskeletal pain

Link found between antibiotic use in babies and asthma

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Cytokines News and Research

Latest Cytokines News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in